Charles River Laboratories
Prices are adjusted according to historical splits.
Vitals
- Today's Low:
- $195.04
- Today's High:
- $199.92
- Open Price:
- $198.88
- 52W Low:
- $181.22
- 52W High:
- $262
- Prev. Close:
- $199.66
- Volume:
- 514689
Company Statistics
- Market Cap.:
- $10.27 billion
- Book Value:
- 60.736
- Revenue TTM:
- $4.09 billion
- Operating Margin TTM:
- 16.41%
- Gross Profit TTM:
- $1.46 billion
- Profit Margin:
- 12.13%
- Return on Assets TTM:
- 5.68%
- Return on Equity TTM:
- 17.21%
Company Profile
Charles River Laboratories had its IPO on 2000-06-23 under the ticker symbol CRL.
The company operates in the Healthcare sector and Diagnostics & Research industry. Charles River Laboratories has a staff strength of 20,000 employees.
Stock update
Shares of Charles River Laboratories opened at $198.88 at the start of the last trading session i.e. 2023-09-12.
The stocks traded within a range of $195.04 - $199.92, and closed at $197.11.
This is a -1.28% slip from the previous day's closing price.
A total volume of 514,689 shares were traded at the close of the day’s session.
In the last one week, shares of Charles River Laboratories have slipped by -5.97%.
Charles River Laboratories's Key Ratios
Charles River Laboratories has a market cap of $10.27 billion, indicating a price to book ratio of 4.1513 and a price to sales ratio of 2.94.
In the last 12-months Charles River Laboratories’s revenue was $4.09 billion with a gross profit of $1.46 billion and an EBITDA of $977.24 million. The EBITDA ratio measures Charles River Laboratories's overall financial performance and is widely used to measure its profitability.
In the trailing 12-month period, Charles River Laboratories’s operating margin was 16.41% while its return on assets stood at 5.68% with a return of equity of 17.21%.
In Q1, Charles River Laboratories’s quarterly earnings growth was a positive 11% while revenue growth was a positive 12.6%.
Charles River Laboratories’s PE and PEG Ratio
- Forward PE
- 17.3913
- Trailing PE
- 19.9682
- PEG
- 1.1951
Its diluted EPS in the last 12-months stands at $10.05 per share while it has a forward price to earnings multiple of 17.3913 and a PEG multiple of 1.1951. A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.
The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Charles River Laboratories’s profitability.
Charles River Laboratories stock is trading at a EV to sales ratio of 3.7191 and a EV to EBITDA ratio of 16.1394. Its price to sales ratio in the trailing 12-months stood at 2.94.
Charles River Laboratories stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.
Balance sheet and cash flow metrics
- Total Assets
- $7.70 billion
- Total Liabilities
- $981.39 million
- Operating Cash Flow
- $-168618000.00
- Capital Expenditure
- $106.88 million
- Dividend Payout Ratio
- 0%
Charles River Laboratories ended 2024 with $7.70 billion in total assets and $0 in total liabilities. Its intangible assets were valued at $7.70 billion while shareholder equity stood at $3.11 billion.
Charles River Laboratories ended 2024 with $212.28 million in deferred long-term liabilities, $981.39 million in other current liabilities, 512000.00 in common stock, $1.54 billion in retained earnings and $2.90 billion in goodwill. Its cash balance stood at $201.59 million and cash and short-term investments were $201.59 million. The company’s total short-term debt was $0 while long-term debt stood at $2.74 billion.
Charles River Laboratories’s total current assets stands at $1.45 billion while long-term investments were $293.79 million and short-term investments were $0. Its net receivables were $788.31 million compared to accounts payable of $120.00 million and inventory worth $262.58 million.
In 2024, Charles River Laboratories's operating cash flow was $-168618000.00 while its capital expenditure stood at $106.88 million.
Comparatively, Charles River Laboratories paid $0 in dividends in 2024.
Other key metrics
- Current Trading Price
- $197.11
- 52-Week High
- $262
- 52-Week Low
- $181.22
- Analyst Target Price
- $249
Charles River Laboratories stock is currently trading at $197.11 per share. It touched a 52-week high of $262 and a 52-week low of $262. Analysts tracking the stock have a 12-month average target price of $249.
Its 50-day moving average was $206.22 and 200-day moving average was $212.09 The short ratio stood at 2.22 indicating a short percent outstanding of 0%.
Around 97.8% of the company’s stock are held by insiders while 9900% are held by institutions.
Frequently Asked Questions About Charles River Laboratories
Similar Industry Stocks (Diagnostics & Research)
Most Active
Top Gainers
Top Losers
About
Charles River Laboratories International, Inc., a non-clinical contract research organization, provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing). The RMS segment produces and sells rodent research model strains and purpose-bred rats and mice for use by researchers. This segment also provides a range of services to assist its clients in supporting the use of research models in research and screening non-clinical drug candidates, including research models, genetically engineered models and services, insourcing solutions, and research animal diagnostic services. The DSA segment offers early and in vivo discovery services for the identification and validation of novel targets, chemical compounds, and antibodies through delivery of non-clinical drug and therapeutic candidates ready for safety assessment; and safety assessment services, such as toxicology, pathology, safety pharmacology, bioanalysis, drug metabolism, and pharmacokinetics services. The Manufacturing segment provides in vitro methods for conventional and rapid quality control testing of sterile and non-sterile pharmaceuticals and consumer products. This segment also offers specialized testing of biologics that are outsourced by pharmaceutical and biotechnology companies; and avian vaccine services that provide specific-pathogen-free (SPF) fertile chicken eggs, SPF chickens, and diagnostic products used to manufacture vaccines. The company also provides contract vivarium operation services to biopharmaceutical clients. Charles River Laboratories International, Inc. was founded in 1947 and is headquartered in Wilmington, Massachusetts.